Lucjan Wyrwicz

Statistics

Publications

Citations

5.4K

H-Index

Active since

2016

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

National Cancer Center Hospital East

KU Leuven

Yonsei University

Memorial Sloan Kettering Cancer Center

Lucjan Wyrwicz is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in oncology, medicine, and cancer immunotherapy.

Publications per year

2016–2025

Publications

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez et al. · Nature · 2021 · 689 citations · Full text

Medicine, Oncology, Pharmacology +17

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Thomas Yau, J.W. Park, Richard S. Finn et al. · Annals of Oncology · 2019 · 648 citations · Full text

Medicine, Oncology, Pharmacology +12

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler et al. · Nature · 2022 · 442 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Josep Tabernero, Eric Van Cutsem, Yung‐Jue Bang et al. · Journal of Clinical Oncology · 2019 · 171 citations

Medicine, Oncology, Pharmacotherapy +14

1–5 of 24